In TNF-related apoptosis-inducing ligand (TRAIL)-resistant glioma cells, co-treatment with nontoxic doses of sodium butyrate and TRAIL resulted in a marked increase of TRAIL-induced apoptosis. This combined treatment was also cytotoxic to glioma cells overexpressing Bcl-2 or Bcl-xL, but not to normal human astrocytes, thus offering an attractive strategy for safely treating resistant gliomas. Cotreatment with sodium butyrate facilitated completion of proteolytic processing of procaspase-3 that was partially blocked by treatment with TRAIL alone. We also found that treatment with sodium butyrate significantly decreased the protein levels of survivin and X-linked inhibitor of apoptosis protein (XIAP), two major caspase inhibitors. Overexpression of survivin and XIAP attenuated sodium butyratestimulated TRAIL-induced apoptosis, suggesting its involvement in conferring TRAIL resistance to glioma cells. Furthermore, the kinase activities of Cdc2 and Cdk2 were significantly decreased following sodium butyrate treatment, accompanying downregulation of cyclin A and cyclin B, as well as upregulation of p21. Forced expression of Cdc2 plus cyclin B, but not Cdk2 plus cyclin A, attenuated sodium butyrate/TRAIL-induced apoptosis, overriding sodium butyrate-mediated downregulation of survivin and XIAP. Therefore, Cdc2-mediated downregulation of survivin and XIAP by sodium butyrate may contribute to the recovery of TRAIL sensitivity in glioma cells.
Introduction
TNF-related apoptosis-inducing ligand (TRAIL) is considered to be a promising candidate for anti-cancer therapy, since the cytotoxic activity of TRAIL is relatively selective for cancer cells compared to normal cells both in vitro and in vivo (Ashkenazi et al., 1999; Walczak et al., 1999) . However, recent studies have shown that many types of cancer cells are resistant to the apoptotic effects of TRAIL (Wang and El-Deiry, 2003; Shankar and Srivastava, 2004) , suggesting that TRAIL alone is ineffective for the treatment of certain cancers. Therefore, to establish effective TRAIL-based cancer therapy, an understanding of the molecular mechanisms that confer TRAIL resistance to cancer cells and identification of the sensitizers capable of overcoming TRAIL resistance is required.
Malignant gliomas, the most common primary brain tumors, are known to invade the surrounding normal brain tissue. This often results in incomplete surgical resection, local recurrence, and poor responses to multimodal therapeutic interventions, such as radiotherapy and chemotherapy (Legler et al., 1999) . Many glioma cells are known to be resistant to TRAIL, despite their expression of the TRAIL receptor (Knight et al., 2001) . Therefore, a new therapeutic strategy should be developed to restore TRAIL-induced apoptotic potency to glioma cells.
The short-chain fatty acid sodium butyrate is capable of inducing cell cycle arrest, differentiation, and apoptosis in a variety of cancer cells (Chen et al., 2003) . In human glioma cells, sodium butyrate has been shown to inhibit proliferation through modulation of the protein levels of various cell cycle regulators Kamitani et al., 2002) . Sodium butyrate most likely acts through inhibition of deacetylases, thus leading to hyperacetylation of chromatin components such as histones and nonhistone proteins, and ultimately to alterations in gene expression (Kruh, 1982) . Several histone deacetylase (HDAC) inhibitors, administered intravenously or intraperitoneally, inhibit tumor growth in animal cancer models of breast, prostate, lung and stomach cancers, neuroblastoma, and leukemia, with little or no toxicity (Shankar and Srivastava, 2004) . Derivatives of butyrate, SAHA, MS-275, and FK228, all of which are capable of acting as HDAC inhibitors, are currently being investigated in clinical trials (Piekarz and Bates, 2004) ; preliminary results suggest their potential applicability in cancer treatment. Recent studies have shown that leukemia, melanoma, mesothelioma, colon cancer, and breast cancer cells can be sensitized with HDAC inhibitors to undergo TRAILmediated apoptosis (Rosato et al., 2003; Zhang et al., 2003; Chopin et al., 2004; Guo et al., 2004; Kim et al., 2004a; Nakata et al., 2004; Neuzil et al., 2004) . However, the underlying mechanisms by which HDAC inhibitors sensitize cancer cells to TRAIL-induced apoptosis are still poorly understood. Recently, upregulation of DR5, a death receptor of TRAIL (Guo et al., 2004; Kim et al., 2004a; Nakata et al., 2004) , downregulation of FLIP (Hernandez et al., 2001; Guo et al., 2004) , or p21 induction (Chopin et al., 2004) has been proposed as the potential mechanisms through which HDAC inhibitors enhance TRAIL-induced apoptosis. In this study, we show that combined treatment with subtoxic doses of sodium butyrate and TRAIL dramatically induces apoptosis in TRAILresistant glioma cells. However, this treatment is not cytotoxic to normal human astrocytes. Furthermore, the present study provides the first evidence that inhibition of Cdc2 activity by sodium butyrate contributes to the recovery of TRAIL sensitivity in glioma cells through downregulation of two major inhibitor of apoptosis proteins (IAPs), survivin and X-linked IAP (XIAP).
Results

Sodium butyrate sensitizes TRAIL-induced apoptosis in glioma cells but not in normal astrocytes
Many human glioma cell lines are resistant to TRAIL, as we have reported previously (Kim et al., 2004b) . First, we investigated whether sodium butyrate could sensitize these glioma cells to TRAIL-induced apoptosis. Four glioma cell lines were treated with sodium butyrate alone, TRAIL alone, or in combination with sodium butyrate and TRAIL for 24 h. While cellular viabilities of glioma cells, assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, were not significantly reduced by treatment with sodium butyrate or TRAIL alone, cell viability was significantly decreased by the combined treatment; both when holding the concentration of TRAIL fixed and varying the concentrations of sodium butyrate, and, conversely, when holding the concentration of sodium butyrate fixed and varying TRAIL ( Figure 1a ). These results demonstrate that the combined treatment with sodium butyrate and TRAIL effectively induces cell death in these TRAIL-resistant glioma cells. Next, we investigated whether this combined treatment affects the viability of normal human astrocytes. The astrocytes were also resistant to either Figure 1 Subtoxic doses of sodium butyrate sensitize human glioma cells but not normal human astrocytes to TRAIL-induced apoptosis. (a) Effect of sodium butyrate and/or TRAIL on the viability of glioma cell lines. Four glioma cell lines were treated with sodium butyrate for 30 min, and further treated with TRAIL for 24 h at the indicated concentrations. Cellular viability was assessed by MTT assay. Graphs represent the average and standard deviation of three individual experiments. (b) Effect of sodium butyrate and/or TRAIL on the cellular viabilities of astrocytes. Human primary astrocytes were treated with TRAIL in the absence or presence of sodium butyrate for 24 h at the indicated concentrations Sensitization of TRAIL-induced apoptosis by sodium butyrate EH Kim et al TRAIL or sodium butyrate alone (Figure 1b) . Furthermore, combined treatment with sodium butyrate and TRAIL did not induce any significant cell death in human astrocytes. These results suggest that the sensitizing regimens using sodium butyrate and TRAIL may be preferentially toxic for glioma cells over normal astrocytes. Next, we investigated whether the apoptosis by this combined treatment could be blocked by overexpression of Bcl-2 or Bcl-xL. Interestingly, cellular viabilities were also significantly reduced in stable cell lines overexpressing Bcl-2 or Bcl-xL (Figure 2a and b) . These results suggest that combined treatment with sodium butyrate and TRAIL may have a therapeutic effect on glioma cells overexpressing Bcl-2 or Bcl-xL, which are resistant to many other chemotherapeutic drugs.
Cotreatment with sodium butyrate and TRAIL recovers incomplete activation of caspases in TRAIL-resistant glioma cells
We examined whether the sensitizing effect of sodium butyrate on TRAIL-mediated apoptosis was associated with the activation of caspases. U87MG or A172 cells were treated with 5 mM sodium butyrate for 16 h, or 100 ng/ml TRAIL alone, or pretreated with sodium butyrate (30 min), followed by TRAIL for the indicated times. Treatment with 5 mM sodium butyrate alone for 16 h did not induce any proteolytic processing of caspases ( Figure 3a) . In response to TRAIL, the 32-kDa procaspase-3 was partially cleaved to a 20-kDa intermediate form after 4 h, but further cleavage into the active p17 subunit was not detected, nor were other caspase processing events in both cell lines. However, treatment with sodium butyrate plus TRAIL induced the cleavage of caspase-3 into the p20 intermediate form at 4 h, and its subsequent cleavage into the active p17 subunit after 8 h in A172 cells. were also progressively processed into their respective active forms after combined treatment. We further assessed the cleavage of several key death substrates that indicate activation of caspases, including FAK (caspase-3), PARP (substrate for csapase-3, -7), and Bid (caspase-8) (Earnshaw et al., 1999) . They were degraded from 8 h after the combined treatment, whereas they were not degraded following treatment with TRAIL or sodium butyrate alone (Figure 3b ). Similar activation patterns of caspases in U87MG cells were also observed in response to sodium butyrate plus TRAIL (Figure 3a and b). These results suggest that TRAIL resistance in these glioma cell lines may be associated with a proteolytic processing blockade of procaspase-3, and a failure in the subsequent caspase amplification cascade, and co-treatment with sodium butyrate may contribute to the relief of proteolytic processing blockade in glioma cells exposed to TRAIL. Caspase-8 has been reported to play a critical role as an initiator caspase in TRAIL-induced apoptosis (Seol et al., 2001 ) and the fundamental activation event of caspase-8 has been reported to be the dimerization of procaspase-8 monomers rather than their cleavage (Boatright and Salvesen, 2003) . Therefore, we first investigated whether caspase-8 is also important for apoptosis induced by the combined treatment with sodium butyrate and TRAIL. Overexpression of CrmA, a viral protein inhibitor of caspase-8 (Zhou et al., 1997) , almost completely blocked the cell death by this combined treatment (Figure 4a ), demonstrating the critical role of caspase-8 in this process. We next examined whether inhibition of caspase-8 activity affects the proteolytic cleavage of procaspase-3 following TRAIL treatment. CrmA overexpression completely inhibited the TRAILinduced cleavage of procaspase-3 into the p20 intermediate form (Figure 4b ). These results suggest that caspase-8 is involved at the initial step of TRAIL-induced proteolytic processing of procaspase-3 in these glioma cells. Combined treatment-induced proteolytic processing of caspase-3 into its active forms was also completely blocked by CrmA overexpression (Figure 4c ).
Combined treatment with sodium butyrate and TRAIL reduces the expression of survivin and XIAP We investigated the possible underlying mechanisms by which sodium butyrate sensitizes glioma cells to TRAIL-induced apoptosis. Recently, upregulation of the TRAIL receptor DR5 by HDAC inhibitors including sodium butyrate has been proposed to be involved in the sensitization of Jurkat and HCT116 colon cancer cells to TRAIL-induced apoptosis (Guo et al., 2004; Kim et al., 2004a; Nakata et al., 2004) . Therefore, we first examined whether sodium butyrate also enhanced TRAIL-induced apoptosis of glioma cells through inhibition of HDAC activity and DR5 upregulation. Acetylation levels of histone H3 and H4 were Western blotting using an anti-Flag Ab was performed to confirm the overexpression of Flag-tagged Bcl-2 or Flag-tagged Bcl-xL in selected cell lines. (b) Effect of the combined treatment with sodium butyrate and TRAIL in the cells overexpressing Bcl-2 or Bcl-xL. U87MG glioma cells overexpressing Bcl-2 or Bcl-xL were treated with 5 mM sodium butyrate plus 100 ng/ml TRAIL for 24 h, and cellular viability was measured by MTT assay significantly increased in U87MG and A172 glioma cells in a dose-and time-dependent manner in response to sodium butyrate (Figure 5a ), demonstrating that their intracellular HDAC activity was inhibited by sodium butyrate treatment. However, basal DR5 protein levels were fairly high in both U87MG cells and A172 cells, and DR5 upregulation following exposure to sodium butyrate was not dramatic. Recently, reduction in the protein levels of the caspase inhibitor FLIP by sodium butyrate has been implicated in the sensitization of colon cancer cells and Jurkat cells to TRAIL-induced apoptosis (Hernandez et al., 2001; Guo et al., 2004) . However, FLIP protein levels were not changed following sodium butyrate treatment in either U87MG or A172 cells (Figure 5a ). These results suggest that other mechanisms may be responsible for the dramatic sensitizing effect of sodium butyrate on TRAIL-induced apoptosis in these glioma cells.
We next examined whether apoptosis induced by combined treatment with sodium butyrate and TRAIL was associated with changes in the levels of apoptosisrelated proteins. Bcl-2 protein levels were not altered in either U87MG cells or A172 cells following treatment with 5 mM sodium butyrate and 100 ng/ml TRAIL, whereas this treatment resulted in slightly decreased BclxL protein levels in A172 cells but not in U87MG cells (Figure 5b ). Both the active form and total protein levels of Akt gradually decreased during apoptosis induced by the combined butyrate/TRAIL treatment. Protein levels of two major IAP proteins, survivin and XIAP, were also significantly reduced during sodium butyratestimulated TRAIL-induced apoptosis, while c-IAP2 protein levels were unchanged. Since many antiapoptotic proteins, including XIAP and Akt, have been recently reported to be substrates of caspases Kirsch et al., 1999; Rokudai et al., 2000) , we examined whether the decrease in the levels of these proteins during apoptosis induced by combined butyrate/TRAIL treatment was correlated with enhanced caspase activity. CrmA overexpression almost completely blocked the downregulation of Akt by combined butyrate/TRAIL treatment (Figure 5c ), suggesting that the decrease in the activity and total protein levels of Akt by the combined treatment resulted from the activation of caspases. In contrast, CrmA overexpression did not completely block downregulation of XIAP. Interestingly, survivin still remained downregulated in CrmA-overexpressing cells treated with sodium butyrate and TRAIL. Together, these results suggest that another non-caspase control mechanism may exist for the downregulation of survivin and XIAP protein levels by sodium butyrate. Sodium butyrate enhances TRAIL-induced apoptosis by downregulation of survivin and XIAP Next, we investigated whether sodium butyrate itself affects the expression of survivin and XIAP. Treatment with sodium butyrate alone led to a significant dose-and time-dependent decrease in survivin protein levels, and, to a lesser extent, a dose-and time-dependent decrease in XIAP protein levels ( Figure 6a ). In contrast, both the activity and total protein levels of Akt were not altered by sodium butyrate treatment. To investigate whether this downregulation of survivin and/or XIAP by sodium butyrate is critical to trigger TRAIL-induced apoptosis, we analysed the cytotoxic effect of sodium butyrate plus TRAIL on stable cell lines overexpressing survivin or XIAP. In both types of cells, apoptosis induced by combined butyrate/TRAIL treatment was considerably, but not completely, attenuated (Figure 6b ). These results suggest that high expression of survivin and/or XIAP may be involved in TRAIL resistance in glioma cells. However, sodium butyrate-mediated downregulation of survivin and XIAP may trigger the completion of Figure 4 Caspase-8 plays a critical role not only in TRAILinduced proteolytic processing of procaspase-3 into the p20 intermediate form but also in sodium butyrate-sensitized TRAILinduced apoptosis. (a) Overexpression of CrmA blocks sodium butyrate-sensitized TRAIL-induced apoptosis. The sublines overexpressing CrmA were treated with 5 mM sodium butyrate plus 100 ng/ml TRAIL for 24 h and the cellular viability was measured using calcein-AM and EthD-1. Data represent means of triplicate determinations. Protein levels of CrmA in the respectively selected stable cell lines are shown in the left panel. (b) CrmA overexpression blocks TRAIL-induced proteolytic processing of procaspase-3. The sublines overexpressing CrmA (clone no. 7) were treated with 100 ng/ml TRAIL alone for the indicated time points and cell extracts were prepared for Western blotting of caspase-3. Cell extracts of U87MG cells treated with 100 ng/ml TRAIL for 16 h were used as a control for Western blotting of caspase-3. (c) CrmA overexpression blocks the proteolytic processing of caspase-3 induced by the combined treatment with sodium butyrate and TRAIL. The sublines overexpressing CrmA (clone no. 7) were treated with 5 mM sodium butyrate and 100 ng/ml TRAIL in combination for the indicated time points and cell extracts were prepared for Western blotting of caspae-3. Cell extracts of U87MG cells treated with sodium butyrate plus TRAIL for 16 h were used as a control for Western blotting Figure 5 Effect of the combined treatment with sodium butyrate and TRAIL on the expression of the proteins associated with intracellular regulators of apoptosis. (a) Changes in the acetylation levels of histone H3, H4 and expression of DR5 or FLIP following treatment with sodium butyrate. U87MG cells or A172 cells were treated with sodium butyrate at the indicated concentrations for 24 h or at 5 mM for the indicated times. Western blotting was performed to detect the changes in the acetylation levels of histone H3 or H4, and protein levels of DR5 or FLIP. a-Tubulin protein levels served as the control for protein loading. (b) Effect of the combined treatment with sodium butyrate and TRAIL on the expression of antiapoptotic proteins. U87MG or A172 cells were treated with 5 mM sodium butyrate and 100 ng/ml TRAIL in combination for the indicated time points, and cell extracts were prepared for Western blotting of the indicated proteins. (c) Effect of CrmA overexpression on the expression of Akt, survivin, and XIAP following the combined treatment. The sublines overexpressing CrmA (clone no. 7) were treated with 5 mM sodium butyrate and 100 ng/ml TRAIL in combination, and cell extracts were prepared for Western blotting procaspase-3 processing initiated by TRAIL, resulting in irreversible cell death.
Sodium butyrate inhibits Cdc2 and Cdk2 activity through modulation of the expressions of various cell cycle regulators
We next investigated the possible upstream signaling pathways involved in sodium butyrate-mediated downregulation of survivin and XIAP. We have recently demonstrated that treatment with roscovitine, an inhibitor of Cdc2 and Cdk2 kinase, results in downregulation of survivin and XIAP in glioma cells (Kim et al., 2004b) . Furthermore, sodium butyrate has previously been reported to increase the expression of p21, a representative CDK inhibitor, in a variety of cancer cells Pellizzaro et al., 2001) . Therefore, we examined expression of various cell cycle regulators in response to sodium butyrate. Consistent with the results of other researchers Pellizzaro et al., 2001) , p21 protein levels were significantly increased by treatment with 5 mM sodium butyrate in both U87MG and A172 cells (Figure 7a ). In contrast, cyclin A and cyclin B protein levels decreased dramatically, whereas Cdk2 and cyclin E protein levels were not significantly altered. While Cdc2 protein levels were slightly decreased only in U87MG cells, Cyclin D protein levels were slightly increased only in A172 cells in response to sodium butyrate treatment. Phosphorylation levels of pRB gradually decreased following sodium butyrate treatment in these glioma cells. RT-PCR analysis demonstrated that mRNA levels of both cyclin A and cyclin B were significantly downregulated by sodium butyrate (Figure 7b ), suggesting that sodium butyrate modulates the expressions of these cyclins at Figure 6 Critical role of survivin and XIAP in conferring glioma cells resistance to TRAIL-induced apoptosis. (a) Effect of sodium butyrate on survivin, XIAP, and Akt protein levels. U87MG and A172 cells were treated with sodium butyrate at the indicated concentrations for 24 h or at 5 mM for the indicated times. Cell extracts were prepared for Western blotting. (b) Effect of survivin or XIAP overexpression on apoptosis induced by the combined treatment with sodium butyrate and TRAIL. Control U87MG cells and U87MG sublines overexpressing survivin or XIAP were treated with 5 mM sodium butyrate and 100 ng/ml TRAIL for 24 h, and cellular viability was measured using calcein-AM and EthD-1. Values from each treatment group are expressed as a percentage relative to the untreated control U87MG cells (100%). Data represent means of triplicate determinations Figure 7 Effect of sodium butyrate on the expressions of cell cycle regulators and activities of Cdc2 and Cdk2. (a) Changes in the protein levels of the cell cycle regulators following treatment with sodium butyrate. U87MG or A172 cells were treated with 5 mM sodium butyrate at the indicated time points, and cell extracts were prepared for Western blotting. (b) Changes in mRNA levels of cyclin A and cyclin B following treatment with sodium butyrate. U87MG cells were treated with 5 mM sodium butyrate at the indicated time points and RT-PCR was performed to detect the mRNAs of cyclin A and cyclin B. (c) Inhibition of Cdc2 and Cdk2 kinase by sodium butyrate. U87MG cells were treated with 5 mM sodium butyrate alone, 100 ng/ml TRAIL alone or 5 mM sodium butyrate plus 100 ng/ml TRAIL for 24 h. Following treatments, cell extracts were prepared and Cdc2 or Cdk2 immune complex kinase assays on histone H1 were performed. Representative results of three independent experiments are shown. Fold change in the respective kinase activity was calculated from liquid scintillation counting of each gel slice the transcriptional level. We next examined whether the kinase activities of Cdc2 and Cdk2 were affected by sodium butyrate treatment. Treatment of U87MG cells with 5 mM sodium butyrate alone or combined with 100 ng/ml TRAIL dramatically inhibited histone H1-associated Cdc2 and Cdk2 activity, whereas treatment with 100 ng/ml TRAIL alone did not (Figure 7c ). Taken together, these results demonstrate that inhibition of Cdc2 and Cdk2 activity by sodium butyrate may result from the combined effects of downregulation of cyclin A and cyclin B plus p21 upregulation.
Forced expression of Cdc2 plus cyclin B attenuates sodium butyrate-stimulated TRAIL-induced apoptosis Next, we investigated whether sodium butyrate-mediated downregulation of Cdc2 and/or Cdk2 activity is critical for its sensitizing effect on TRAIL-induced apoptosis. U87MG cells were co-transfected with expression vectors encoding Cdc2 plus cyclin B or Cdk2 plus cyclin A, and cellular viability was assessed following combined treatment with sodium butyrate and TRAIL. Interestingly, co-expression of Cdc2 plus cyclin B, but not Cdk2 plus cyclin A, considerably attenuated apoptosis induced by the combined treatment (Figure 8a ). We further examined whether this attenuating effect on apoptosis by co-expression of Cdc2 and cyclin was directly associated with the modulation of survivin and XIAP protein levels. U87MG cells were transfected with expression vectors encoding Cdc2 plus cyclin B or Cdk2 plus cyclin A, after which cells were treated with sodium butyrate. Forced expression of Cdc2 with cyclin B, but not Cdk2 with cyclin A, led to a considerable recovery of survivin protein levels, which were significantly downregulated by sodium butyrate treatment (Figure 8b ). Sodium butyrate-mediated downregulation of XIAP protein levels was similarly modulated by expression of these cell cycle regulators. These results suggest that inhibition of Cdc2 activity is critical for downregulation of survivin and XIAP, providing one mechanism by which sodium butyrate overcomes barriers against TRAIL-induced apoptosis of glioma cells.
Other HDAC inhibitors also sensitize glioma cells to TRAIL-induced apoptosis through Cdc2-mediated downregulation of survivin and XIAP We investigated whether other HDAC inhibitors could sensitize glioma cells to TRAIL-induced apoptosis via the same mechanism that was observed with sodium butyrate. Cotreatment with trichostatin A (TSA) or suberic bishydroxamate (SBHA) significantly enhanced TRAIL-induced apoptosis in U87MG cells (Figure 9a ). Neither DR5 nor FLIP protein levels were significantly altered by TSA or SBHA treatment (Figure 9b ). However, both cyclin A and cyclin B protein levels dramatically decreased in response to either TSA or SBHA treatment in a dose-dependent manner. Experiments using the promoter-luciferase reporter of cyclin A or cyclin B clearly demonstrated that the respective treatment with sodium butyrate, TSA, or SBHA downregulated the promoter activities of cyclin A and cyclin B in a dose-dependent manner, suggesting that these HDAC inhibitors commonly downregulate cyclin A and cyclin B at the transcriptional level (Figure 9c ). Interestingly, p21 protein levels were significantly upregulated by SBHA treatment, but not by TSA treatment (Figure 9b ). Cdc2 protein levels were slightly decreased only by SBHA. However, pRB phosphorylation levels were dramatically downregulated by treatment with either SBHA or TSA. Furthermore, Cdc2 kinase activity on histone H1 was also inhibited by treatment with TSA or SBHA (Figure 10a ), as seen with sodium butyrate treatment (Figure 7c ). Survivin and XIAP protein levels were also downregulated following TSA or SBHA treatment (Figure 10b) , as was observed following sodium butyrate treatment (Figure 6a) . These results therefore suggest that HDAC inhibitors may sensitize glioma cells to TRAIL-induced apoptosis through Cdc2-mediated downregulation of survivin and XIAP in common.
Discussion
Malignant gliomas, the most common primary brain tumors, are known to invade surrounding normal brain tissue, which results in incomplete surgical resection and a high frequency of local recurrence. Moreover, malignant gliomas remain poorly responsive to multimodal therapeutic interventions, including radiotherapy and chemotherapy (Legler et al., 1999) . The resistance of glioblastoma multiforme to treatments is related to its cellular heterogeneity (Misra et al., 2000) and the exceptional migratory nature of the tumor cells, which are able to diffusely infiltrate normal brain tissue (Lipinski et al., 2003) . Due to this poor prognosis and the absence of successful therapeutics for glioma patients, new therapeutic paradigms for the treatment of malignant gliomas need to be explored.
For effective cancer therapeutics, it is very important to induce apoptosis specifically in malignant tumor cells, but not in normal cells. TRAIL is a recently identified member of the TNF family that is capable of inducing apoptosis in various tumor cells with minimal toxicity to normal cells (Wiley et al., 1995) . In this regard, TRAIL is an attractive candidate for cancer treatment. However, various types of cancer cells, including breast, prostate, ovarian and lung carcinoma, multiple myeloma, leukemia, and glioma cells, are resistant to apoptosis induced by TRAIL (Shankar and Srivastava, 2004) . Therefore, use of TRAIL alone is not an appropriate option for treating these types of cancer. Combination therapy may sensitize TRAIL-resistant cancer cells to TRAIL-induced apoptosis. Resistance to TRAIL appears to occur through the modulation of various molecular targets, including differential expression of death receptors, constitutively active Akt and NF-kB, overexpression of c-FLIP, mutations in Bax and Bak, and defects in the release of mitochondrial proteins, in resistant cells (Shankar and Srivastava, 10 Both TSA and SBHA downregulate Cdc2 activity and protein levels of survivin and XIAP. (a) Inhibition of Cdc2 activity following treatment with HDAC inhibitors. U87MG cells were treated with 100 ng/ml TRAIL, 5 mM sodium butyrate, 100 ng/ml TSA, or 80 mM SBHA for 24 h. Following treatments, cell extracts were prepared and Cdc2 immune complex kinase assays on histone H1 were performed. Representative results of three independent experiments are shown. Fold changes in the respective kinase activity were calculated from liquid scintillation counting of each gel slice. (b) Effect of TSA or SBHA on the expression of survivin and XIAP. U87MG cells were treated with 100 ng/ml TSA or 80 mM SBHA for 24 h at the indicated concentrations. Cell extracts were prepared for Western blotting of survivin and XIAP 2004). Moreover, high expression of IAPs may also contribute to TRAIL resistance, since IAPs such as survivin, XIAP, c-IAP1, and c-IAP2 block apoptosis at the effector phase, a point at which multiple signaling pathways converge .
HDAC inhibitors are potent regulators of gene expression through their effect on the acetylation of core histones (Marks et al., 2001; Vigushin and Coombes, 2002) . HDAC inhibitors have recently emerged as promising chemotherapeutic agents. Inhibition of HDACs may contribute to the induction of cell cycle arrest during the G 1 and/or G 2 phase, differentiation, and/or apoptosis in various cancer cells (Marks et al., 2001) . Several HDAC inhibitors can halt tumor growth in animal models with little toxicity, while the inhibition of HDAC is normally not sufficient to cause cell death in nontumor cells (Vigushin et al., 2001; Atadja et al., 2004) . This selectivity for tumor cells makes these compounds particularly attractive for cancer therapy, and several newly developed HDAC inhibitors have been tested on cancer patients in clinical trials (Piekarz and Bates, 2004) . Among the short-chain fatty acids, butyrate appears to have the most profound effect on growth inhibition and differentiation in various kinds of cancer cells (Heerdt et al., 1994 (Heerdt et al., , 1997 . It is often suggested that the antitumorigenic effects of sodium butyrate are exerted by inhibition of HDACs (Bernhard et al., 1999; Siavoshian et al., 2000) . In glioma cells, sodium butyrate has been reported to inhibit not only cell proliferation Kamitani et al., 2002) but also invasion as well as VEGF secretion (Sawa et al., 2002) . These results suggest that sodium butyrate may be a useful therapeutic agent for treating malignant gliomas. However, the molecular mechanisms underlying these effects have not been fully understood.
Recent studies have shown that leukemia, melanoma, mesothelioma, colon cancer, and breast cancer cells can be sensitized with HDAC inhibitors to undergo TRAIL-mediated apoptosis (Rosato et al., 2003; Zhang et al., 2003; Chopin et al., 2004; Guo et al., 2004; Kim et al., 2004a; Nakata et al., 2004; Neuzil et al., 2004) , suggesting that combining HDAC inhibitor with TRAIL may be a promising therapeutic strategy. Sodium butyrate has been proposed to disrupt the association of HDAC with Sp1, which in turn may lead to the decondensation of local chromatin, activate the transcription of DR5, and activate TRAILinduced apoptotic signaling pathways in colon cancer cells (Kim et al., 2004a) . Decreased expression of FLIP, which functions as a dominant negative inhibitor of caspase-8 due to its structural resemblance to caspase-8 without proteolytic activity, has also been proposed to be involved in this sensitizing effect of sodium butyrate (Hernandez et al., 2001) . In our study, combined treatment with sodium butyrate and TRAIL, but not either agent alone, significantly induced apoptosis in various glioma cell lines. However, no significant upregulation of DR5 occurred, and FLIP protein levels were not altered by sodium butyrate treatment, suggesting that other mechanisms may exist for sodium butyrate-enhanced TRAIL-induced apoptosis in glioma cells.
Previous reports have indicated that survivin and XIAP are overexpressed in gliomas and that these high expression levels correlate with abbreviated patient survival, unfavorable prognosis, and resistance to therapy (Chakravarti et al., 2002) . In our study, survivin and XIAP protein levels were significantly suppressed following treatment with sodium butyrate, and the extent of survivin downregulation was greater than that of XIAP. However, apoptosis was not induced in glioma cells by treatment with 5 mM sodium butyrate alone. These results suggest that downregulation of survivin and XIAP by sodium butyrate may not be sufficient to trigger activation of caspases in these glioma cells. Interestingly, the 32-kDa procaspase-3 was partially cleaved to a 20-kDa intermediate form at 4 h following treatment with TRAIL, but further cleavage into the active p17 subunit did not occur in glioma cells, indicating that the proteolytic processing of procaspase-3 can be primed, but not completed by TRAIL. Reportedly, caspase-3 is initially synthesized as an inactive 32-kDa precursor, which is subsequently processed by proteolytic cleavage at ESMDkS (amino acids 25-29) and IETDkS (amino acids 172-176) to produce the mature caspase-3 (Nicholson et al., 1995) . Cleavage at the IETDkS site seems to occur first, yielding a mature p12 subunit and a p20 intermediate product (Han et al., 1997) . Subsequently, a cleavage occurs at the ESMDkS site in the p20 intermediate, yielding the mature p17 subunit. Together, the p12 and p17 subunits then form the mature caspase-3. In TRAIL-induced apoptosis, caspase-8, rather than caspase-10, has been reported to play a critical role as an initiator caspase (Seol et al., 2001; Suliman et al., 2001) . The fundamental activation event of caspase-8 has been reported to be the dimerization of procaspase-8 monomers rather than their cleavage (Boatright and Salvesen, 2003) . Instead, the cleavage event is thought to provide stability to the dimer generated during death-inducing signaling complex (DISC) formation. To examine the role of caspase-8 in our system, we tested the effect of caspase-8 inhibition on the proteolytic cleavage of procaspase-3 following TRAIL treatment. As shown in Figure 4b , overexpression of CrmA, a viral protein inhibitor of caspase-8, completely inhibited the TRAILinduced cleavage of procaspase-3 into the p20 intermediate form, suggesting that caspase-8 activity may be required for this initial proteolytic processing step of procaspase-3 in our system. Therefore, treatment with TRAIL alone may induce dimerization of procaspase-8, leading to partial activation that is sufficient for initial proteolytic processing of procaspase-3 into p20, but not for the autoproteolytic processing of procaspase-8 into its active forms. Sun et al. (2002) have reported that XIAP does not inhibit the initial processing of procaspase-3 into its p20 intermediate form by caspase-8, but does inhibit the caspase activity of p20/p12 and autocatalytic processing of p20 into p17. Moreover, ubiquitin-protein ligase activity of XIAP has been reported to promote proteasomal degradation of active form caspase-3, but not procaspase-3 (Suzuki et al., 2001) . Many studies have also established the role of survivin in apoptosis, and suggested that its antiapoptotic function is related to its ability to directly or indirectly inhibit caspases (Zaffaroni and Daidone, 2002) . Therefore, it is very possible that XIAP and survivin overexpressed in glioma cells play a critical role in blocking of the complete proteolytic processing of the p20 intermediate form into the p17 subunit of caspase-3 following exposure to TRAIL. However, after combined treatment with sodium butyrate and TRAIL, reduction of survivin and XIAP protein levels by sodium butyrate may allow the complete autoprocessing cascade of the p20 intermediate form that is generated by TRAIL into qthe p17 active subunit and subsequently amplify the activation of other caspases. Therefore, downregulation of survivin and XIAP may be one mechanism by which sodium butyrate overcomes TRAIL resistance in glioma cells. Overexpression of either survivin or XIAP reduced the degree of apoptosis induced by sodium butyrate/TRAIL treatment, thereby highlighting the functional significance of sodium butyratemediated downregulation of survivin and/or XIAP during apoptosis.
Recently, we have shown that inhibition of Cdc2 activity by roscovitine downregulates survivin and XIAP, thereby contributing to enhancement of TRAIL-induced apoptosis (Kim et al., 2004b) . Moreover, Chopin et al. (2004) have reported that butyrate and TRAIL synergistically induce apoptosis in breast cancer cells and that this process requires p21. p21 is a representative inhibitor of cyclin-dependent kinases (Cdks) (Brugarolas et al., 1999) . Therefore, in the present study, we further examined the underlying mechanisms involved in sodium butyrate-mediated downregulation of survivin and XIAP by investigating whether it was also associated with the inhibition of Cdk activity. In our study, p21 protein levels were significantly enhanced in U87MG and A172 cells following sodium butyrate treatment. In contrast, cyclin A and cyclin B protein levels were significantly reduced by the same treatment. Not only histone H1-associated Cdc2 and Cdk2 kinase activity but also endogenous phosphorylation levels of pRB were also significantly decreased following sodium butyrate treatment. Very interestingly, exogenously expressed cyclin B plus Cdc2, but not cyclin A plus Cdc2, suppressed sodium butyrateenhanced TRAIL-induced apoptosis. Downregulation of survivin and XIAP by sodium butyrate was also alleviated by this forced co-expression of Cdc2 plus cyclin B, but not by that of Cdk2 plus cyclin A. Taken together, these results suggest that suppression of Cdc2 activity by sodium butyrate plays a critical role in the reduction of survivin and XIAP protein levels. In the present study, we also present evidence that TSA and SBHA, HDAC inhibitors classified as hydroxamic acids (Vigushin and Coombes, 2002) , also sensitize glioma cells to TRAIL-induced apoptosis through inhibition of Cdc2 activity and the subsequent downregulation of survivin and XIAP. Recently, various HDAC inhibitors have been shown to upregulate p21 through the transcriptional control (Gui et al., 2004; Yokota et al., 2004) . However, p21 was not upregulated by treatment with TSA, although the sensitizing effect of TSA on TRAIL-mediated apoptosis was similar to that of sodium butyrate or SBHA (Figures 1a and 9a) . These results suggest that p21 upregulation itself may not be essential for the reduction of survivin and XIAP protein levels, as well as for the sensitizing effect of these HDCA inhibitors on TRAIL-induced apoptosis. We further investigated the role of p21 in sodium butyrate-facilitated TRAIL-induced apoptosis using isogenic colon cancer cell lines differing only in p21 status. HCT116 p21 þ / þ cells were relatively sensitive to TRAIL and TRAIL-mediated apoptosis was significantly potentiated by cotreatment with sodium butyrate. However, HCT116 p21À/À cells showed similar responses (Supplementary Figure 1) , indicating that p21 may not play a critical role in apoptosis induced by sodium butyrate plus TRAIL in these cells, and further suggesting that the requirement of p21 in HDAC inhibitor-facilitated TRAIL-mediated apoptosis may differ according to the cell type. In contrast, both cyclin A and cyclin B protein levels were significantly downregulated by either TSA or SBHA. Our RT-PCR analysis and experiments using promoter-luciferase reporter clearly demonstrated that treatment with HDAC inhibitors transcriptionally downregulates cyclin A and cyclin B (Figures 7b and  9c ). Although downregulation of cyclin A and cyclin B mRNA by TSA has been previously reported (Nair et al., 2001) , we show here for the first time that the transcriptional downregulation of cyclin A and cyclin B mRNA may be a common effect of HDAC inhibitors, including sodium butyrate, TSA, and SBHA, on glioma cells. Future work will be needed to assess whether NF-Y, a transcriptional factor complex that binds to CCAAT boxes located in the cyclin A (Kramer et al., 1997) and cyclin B (Katula et al., 1997) gene promoters, may be targeted by HDAC inhibitors for downregulation of cyclin A and cyclin B. Taken together, the inhibition of Cdc2 activity by HDAC inhibitors may result from the combined effects of transcriptional repression of cyclin A and cyclin B plus transcriptional upregulation of p21. Subsequently, this decreased Cdc2 activity by HDAC inhibitors leads to the reduction of survivin and XIAP protein levels, contributing to the recovery of TRAIL sensitivity in glioma cells (summarized in Figure 11 ).
In our study, treatment with sodium butyrate and TRAIL did not enhance TRAIL-induced apoptosis in normal human astrocytes, whereas the same treatment significantly induced apoptosis in various human glioma cells. Moreover, overexpression of either Bcl-2 or Bcl-xL did not block apoptosis induced by combined butyrate/ TRAIL treatment. Therefore, co-treatment with sodium butyrate and TRAIL is a potentially safe and attractive treatment strategy against intractable human malignant gliomas, particularly in cases where resistance to apoptosis induced by anticancer drugs is due to overexpression of either Bcl-2 or Bcl-xL.
Materials and methods
Chemicals and antibodies (Abs)
Recombinant human TRAIL/Apo2 ligand was from KOMA Biotech Inc. (Korea). Calcein-AM and ethidium homodimer-1 (Etd-1) were from Molecular Probe (Eugene, OR, USA). Sodium butyrate, TSA, and SBHA were obtained from Sigma (St Louis, MO, USA). The following survivin, FLIP, and XIAP (Stressgen, British Columbia, Canada); Rb, FAK, cyclin A, cyclin B, cyclin D, cyclin E, Cdc2, Cdk2, and Myc (Santa Cruz Biotechnologies, Santa Cruz, CA, USA) ; anti-phospho-Akt, Akt, and Bid (Cell Signaling, Beverly, MA, USA); anti-Flag M2 (Sigma, St Louis, MO, USA); anti-CrmA (BD Pharmingen, San Diego, CA, USA); anti-a-tubulin and DR5 (Calbiochem., San Diego, CA, USA); anti-acetylated histone H3, acetylated histone H4 and anti-PARP (Upstate biotechnology, Lake Placid, NY, USA); horseradish peroxidase-conjugated anti-rabbit IgG and horseradish peroxidase-conjugated anti-mouse IgG HRP (Zymed Laboratories, Inc., South San Francisco, CA, USA).
Culture of glioma cell lines and normal human astrocytes
The human malignant glioma cell lines U87MG, U251MG, A172, and T98 were cultured in Dulbecco's modified Eagle's medium (DMEM) (GIBCO-BRL, Life Technologies, NY, USA) supplemented with 10% fetal bovine serum and antibiotics (GIBCO-BRL, Life Technologies, NY, USA). The primary cultures of normal human astrocytes were prepared from 14-week-gestation fetal cerebrum tissues as described previously (Kim, 1985; Kim et al., 1986) . Human astrocyte cultures were subcultured in DMEM containing 10% fetal bovine serum every 2 weeks and cell cultures passage number less than 5 were used in the present study. Immunofluorescence study indicated that better than 99% of cells expressed glial fibrillary acidic protein (GFAP)-positive immunoreactivity, a cell-type-specific marker for astrocytes. Permission to use human brain tissues for research was granted by the Ethics Committee of the University.
Measurement of cellular viability
Cellular viability was assessed by MTT assay. Cells (5 Â 10 3 cells/well) were plated in a 96-well plate. Following treatment, the MTT stock solution (5 mg/ml in PBS) was added to the medium, and incubated with cells at 371C for 3 h to allow cell-mediated reduction of MTT. The absorbance was measured at 540 nm in a microtiter plate reader. Alternatively, the cell viability was assessed by double labeling of cells with 2 mM calcein-AM and 4 mM Etd-1. The calcein-positive live cells and Etd-1-positive dead cells were visualized using a fluorescence microscope (Nikon Diaphot 300, Japan).
Immunoblotting
Cells were washed in PBS and lysed in boiling sodium dodecyl sulfate/polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer (62.5 mmol/l, Tris (pH 6.8), 1% SDS, 10% glycerol, and 5% b-mercaptoethanol). The lysates were boiled for 5 min, separated by SDS-PAGE, and transferred to an Immobilon membrane (Millipore, Bedford, MA, USA). After blocking nonspecific binding sites for 1 h by 5% skim milk, membranes were incubated for 2 h with specific Abs. Membranes were then washed three times with TBST and incubated further for 1 h with horseradish peroxidase-conjugated anti-rabbit, -mouse or -goat Ab. Visualization of protein bands was accomplished using ECL (Amersham Life Science, Buckinghamshire, UK).
RT-PCR
Total RNA was isolated from U87MG cells treated with 5 mM sodium butyrate for the indicated time points using RNAZolB (Tel-Test, Friendswood, TX, USA). Total RNA (2 mg) from each cell culture was reverse transcribed using oligo-dT primers and AMV reverse transcriptase (TaKaRa, Otsu, Shiga). The cDNAs were amplified by PCR (941C for 30 s, 601C for 30 s and 721C for 1 min) with Taq DNA polymerase. To ensure exponential amplification, four aliquots were removed from each PCR assay at cycles 20, 25, 30, or 35 cycles (which were determined in preliminary experiments to produce the weakest detectable PCR product for each gene) and every 2-4 cycles thereafter. Amplified products were analysed by agarose gel electrophoresis at cycles within the linear range of mRNA amplification. The sequences of oligonucleotide primers used for RT-PCR and the expected transcript sizes are as follows: cyclin A, 5 0 -TCCAAGAG GACCAGGAGAATATCA-3 0 and 5 0 -TCCTCATGGTAG TCTGGTACTTCA-3 0 ; cyclin B1, 5 0 -AAGAGCTTTAAA CTTTGGTCTGGG-3 0 and 5 0 -CTTTGTAAGTCCTTGATTT ACCATG-3 0 ; GAPDH, 5 0 -CGTCTTCACCACCATGGA GA-3 0 and 5 0 -CGGCCATCACGCCACAGTTT-3 0 .
Cdc2 and Cdk2 immune complex kinase assay
After treatment of U87MG cells with HDAC inhibitor alone or sodium butyrate plus TRAIL as indicated, cells were lysed in buffer A (1% Nonidet P-40, 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 10 mg/ml aprotinin, 10 mg/ml leupeptin, 20 mM NaF, 1 mM Na 3 VO 4 , 10 mg/ml PMSF) at 41C for 15 min. Cell lysates were cleared by centrifugation at 13 000 rpm for 15 min. Protein concentrations were quantitated by Bio-Rad protein Figure 11 Schematic diagram of the apoptotic pathway induced by the combined treatment with HDAC inhibitor and TRAIL. In TRAIL-resistant glioma cells, the 32-kDa procaspase-3 is partially cleaved to a 20-kDa intermediate form in response to TRAIL, but further cleavage into the active p17 subunit and other caspase processing events do not occur. HDAC inhibitors suppress Cdc2 activity by the combined effects of downregulation of cyclin A and cyclin B plus p21 upregulation. Cotreated HDAC inhibitors facilitate completion of proteolytic processing of procaspase-3, which is partially blocked by treatment with TRAIL alone, through inhibition of the Cdc2 activity and the subsequent downregulation of XIAP and survivin assay. A total of 500 mg of protein was used for each immunoprecipitation. Cdc2 or Cdk2 in cell extracts was incubated with anti-Cdc2 or anti-Cdk2 Ab (1 mg/reaction) for 3 h at 41C, respectively. 15 ml of protein A/G-agarose (Oncogene Research Products, Cambridge, MA, USA) was added into the mixture, which was then further incubated for 1 h. Immune complexes were centrifuged at 2500 r.p.m for 5 min and the precipitates were washed three times with buffer A and twice with kinase buffer (50 mM Tris-HCl (pH 7.5), 10 mM MgCl 2 , 1 mM DTT). Cdc2 or Cdk2 kinase assay on histone H1 was performed by mixing the respective immune complexes with 5 mg of histone H1 and 10 mCi of [g-32 P]ATP in 30 ml of kinase buffer. The kinase reaction was performed at 301C for 30 min and then terminated with 2 Â SDS-PAGE sample buffer. The reaction mixtures were resolved by SDS-PAGE analysis. Gels were stained with Coomassie Blue staining solution and dried. The extent of phosphorylation was measured by liquid scintillation counting of the gel slices of each substrate.
Establishment of the stable U87MG cell lines overexpressing Bcl-2, Bcl-xL, CrmA, XIAP, or survivin U87MG cells were transfected with the following: a mammalian expression vector containing Flag-tagged bcl-2 cDNA and bcl-xL (Huang et al., 1997) (kindly provided by Dr A Strasser, The Walter and Eliza Hall Institute of Medical Research, Australia); a vector containing CrmA cDNA (Tewari et al., 1995) , kindly provided by Professor VM Dixit (University of Michigan Medical School); a vector containing Myc-tagged XIAP (Nomura et al., 2003) (kindly provided by Professor T Nomura, Oita Medical University, Japan). Stable cell lines overexpressing Bcl-2 or Bcl-xL were selected in fresh media containing puromycin (4 mg/ml). Overexpression of Bcl-2 or Bcl-xL in the stable cell lines was analysed by Western blotting using anti-Flag Ab. Stable cell lines overexpressing CrmA or XIAP were selected in fresh media containing G418 (500 mg/ml). Overexpression of CrmA in the stable cell lines was analysed by Western blotting using anti-CrmA Ab, while overexpression of XIAP in the respective stable cell lines was analysed using anti-c-Myc Ab (9E10). To establish stable cell lines overexpressing survivin, U87MG cells were co-transfected with a flag/survivin fusion protein expression vector (Kobayashi et al., 1999) , kindly provided by Professor T Tokuhisa (Chiba University Graduate School of Medicine, Japan), and pcDNA3. Transfected cells were selected with fresh media containing G418 (500 mg/ml) and overexpression of survivin was analysed by Western blotting using anti-Flag Ab.
Expression of Cdc2, Cdk2, cyclin A or cyclin B by transient transfection U87MG cells were plated into 24-well plates at 5 Â 10 4 cells/well. After 24 h, cells were transfected with the plasmid encoding Cdc2, Cdk2 (kindly provided by Dr Sander van den Heuvel, Massachusetts General Hospital), cyclin A, or cyclin B (kindly provided by Dr Paul Robbins, University of Pittsburgh) at the indicated concentrations using Lipofectamine Plus reagent (Gibco BRL, Grand Island, NY, USA) following the manufacturer's instructions. Transfected cells were incubated for 24 h and then further treated with 5 mM sodium butyrate and/or 100 ng/ ml TRAIL for 24 h. Transfection efficiency, assessed using a green fluorescence protein-encoding plasmid (pEGFP-C1; from Promega), reached about 70% in these experiments. Cellular viability was assessed using calcein-AM and Etd-1 as described above. To further confirm the expression of transgenes, Western blotting of the transfected proteins was performed.
Transfection and luciferase assays U87MG cells were seeded at 5 Â 10 5 cells in 60 mm culture dishes. The following day, 60-80% confluent cells were transiently transfected in duplicate with 1 mg of pCyclin A-Luc or pCyclin B-Luc, the reporter construct containing the promoter of human cyclin A or cyclin B1 (kindly provided by Dr DY Shin, Dankook University College of Medicine), together with 0.2 mg of pCMV-b-gal reporter plasmid using Lipofectamine Plus reagent (Gibco BRL, Grand Island, NY, USA) following the manufacturer's instructions. In all transfection assays, pSV-luc reporter plasmid was transfected as negative control, while the transfection of pCMV-b-gal reporter plasmid was carried out to assess transfection efficiency. Transfected cells were incubated in serum-containing media for 24 h and luciferase activity was measured in 20 ml of cell lysates using a luciferase assay system (Promega, Madison, WI, USA) on a TD-20/20 Luminometer (Turner designs, Sunnyvale, CA, USA) for 12 s. Luciferase activity was normalized for b-galactosidase activity in cell lysates.
